Ovid Therapeutics Inc.
NASDAQ:OVID · NASDAQ Global Select
-$0.11 today
Vol 7.41M · Avg 3.07M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $94.1M |
| Short-term Investments | $61.5M |
| Other Current | $4.6M |
| Total Current Assets | $160.1M |
| PP&E (Net) | $11.5M |
| Long-term Investments | $42.0M |
| Other Non-current | $12.0M |
| Total Non-current Assets | $65.5M |
| Total Assets | $225.6M |
Analysis
Selected assets total $225.6M for Latest. The largest visible component is Cash & Equivalents at $94.1M, about 41.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.2M -50.0% | $26.3M -2.7% | $27.0M -39.7% | $44.9M -76.1% | $187.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $56.5M +111.0% | $26.8M -66.0% | $78.8M -6.3% | $84.1M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $20.8M | $0 -100.0% | $1.0K +99900.0% | $1 -100.0% | $2.7M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $90.4M +61.7% | $55.9M -49.0% | $109.6M -16.6% | $131.4M -31.0% | $190.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 -100.0% | $13.2M -9.8% | $14.7M -8.8% | $16.1M +6520.0% | $242.8K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 -100.0% | $92.0K -54.0% | $200.0K -10.0% | $222.1K +35.4% | $164.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $64.7M +208.5% | $21.0M +19.0% | $17.6M +213.5% | $5.6M +57.8% | $3.6M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | -$4.2M -318.4% | $1.9M -0.5% | $1.9M -1.5% | $2.0M +1949.2% | $96.1K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $60.5M +67.0% | $36.2M +5.2% | $34.4M +44.1% | $23.9M +487.5% | $4.1M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $150.9M +63.8% | $92.2M -36.0% | $144.0M -7.2% | $155.3M -20.2% | $194.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $2.0M -38.7% | $3.2M -13.8% | $3.7M +89.6% | $2.0M -72.6% | $7.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 -100.0% | $1.0K | $0 | $0 -100.0% | $3.9M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $8.3M -21.2% | $10.5M -8.3% | $11.5M +64.1% | $7.0M -52.8% | $14.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 -100.0% | $30.0M +3000099900.0% | $1 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $12.0M -10.7% | $13.4M -70.0% | $44.8M +179.7% | $16.0M | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $20.3M -15.3% | $23.9M -57.4% | $56.2M +144.6% | $23.0M +55.4% | $14.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $130.0K +83.1% | $71.0K +0.0% | $71.0K +0.8% | $70.5K +0.2% | $70.4K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$321.7M -5.7% | -$304.3M -9.5% | -$277.9M -23.2% | -$225.5M -31.6% | -$171.4M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$202.0K -477.1% | -$35.0K | $0 +100.0% | -$42.2K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 +100.0% | -$0 | $0 +100.0% | -$1 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $130.7M +91.5% | $68.2M -22.3% | $87.8M -33.6% | $132.3M -26.4% | $179.7M | $9.1B | $7.7B | $3.3B |
| Total Debt | $13.4M -9.1% | $14.8M -7.8% | $16.0M -3.2% | $16.5M | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | $266.0K +102.3% | -$11.5M -4.6% | -$11.0M +61.0% | -$28.3M +84.9% | -$187.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
MacroGenics, Inc.
NASDAQ:MGNX
$259.66M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.81M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$208.19M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
InflaRx N.V.
NASDAQ:IFRX
$130.74M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.61M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$88.65M
ImageneBio Inc
NASDAQ:IMA
$64.63M
Clene Inc.
NASDAQ:CLNN
$61.64M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.21M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does OVID have?
Ovid Therapeutics Inc. (OVID) reported $13.15M in cash and equivalents in fiscal 2025.
How much debt does OVID carry?
Ovid Therapeutics Inc. (OVID) reported $13.42M of total debt, with net debt of $266,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.